Next Generation Flow™ MM MRD Solution
Why Choose Next Generation Flow™?
The Next Generation Flow™ Solution provides a trusted, ultrasensitive, highly accessible, and standardized CE-IVD flow cytometric solution for Multiple Myeloma MRD assessment in bone marrow, capable of detecting minimal residual disease with a Limit of Detection as low as 2*10-6.
Standardized MM MRD assessment using Next Generation Flow™, supporting timely and reliable results for confident interpretation.
✔ TRUSTED
- Validated & IMWG endorsed method - Built on the research and validation work of the EuroFlow™ consortium as recommended by the International Myeloma Working Group
- Standardized CE-IVD solution – comparable MRD assessment across all samples in real-world data and across clinical trials
✔ ULTRASENSITIVE
- Limit of detection (LOD) down to 2*10-6 cells When recording 10 million nucleated cells
✔ HIGHLY ACCESSIBLE
- Implementable in your hospital – Broad footprint of instrumentation and ready-to-go reagents and software
- No baseline diagnostic sample required – Enabling implementation at different stages of the treatment pathway, according to institutional practice
Support your hospital’s Myeloma Unit by implementing efficient, trusted, and ultrasensitive Next Generation Flow™ MM MRD assessment in your laboratory.
Next Generation Flow™ – your End-to-End Standardization solution
Support consistency and reliability with:
- EuroFlow™-approved protocols.1
- Ready-to-use, validated CE-IVD solution: MM MRD Kit.2
- Expert-guided automated analysis and reporting powered by expert-developed databases with Infinicyt™ Software.2
Explore Our Next Generation Flow™ MM MRD Kit
A CE-IVD plasma cell panel, based on the IMWG recommended EuroFlow™ panel and designed to support accurate and reproducible MRD assessment in Multiple Myeloma, including in patients receiving anti-CD38 therapies.2,3
Learn how to make standardized and ultrasensitive MRD testing accessible to your laboratory
Listen to the experts
Request a consultation
